Claire Henchcliffe, one of the studys principal investigators and the chair of the neurology department of the University of California Irvine School of Medicine, called the data collected for bemdaneprocel extremely encouraging. While this is a small openlabel study meeting the studys primary objective for safety and tolerability along with initial improvements seen in clinical outcomes represents a great step forward Henchcliffe said in a statement from Bluerock